SAFETY ALERT: Dolutegravir (Tivicay™, Triumeq™) use in pregnancy

By /

On June 7, 2018 – Health Canada issued a warning regarding the possible risk of neural tube defects associated with dolutegravir use during early pregnancy. This warning is based on preliminary findings from an observational study in Botswana, which identified 4 infants with neural tube defects born to women who had been treated with dolutegravir at the time of conception.

For more information: Click here to view the Health Canada advisory

In collaboration with the BC Centre for Excellence in HIV/AIDS, the Oak Tree Clinic at BC Women’s Hospital and Health Centre has developed Dolutegravir prescribing guidelines for pregnancy and women of reproductive potential.

Amendment: On July 31, 2019, the Oak Tree Clinic guidelines were updated to reflect new information. Click here to view the most recent updates to the Oak Tree Clinic resources for healthcare providers (scroll down the page to Antiretroviral Drug Information)

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search